Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Cancer Type/Condition:  Liver cancer, adult primary
Stage/Subtype:  advanced adult primary liver cancer
Country:  U.S.A.
Trial Type:  Treatment
Results 1-25 of 46 for your search:
Start Over
Sorafenib Tosylate in Treating Patients with Advanced Liver Cancer and Hepatitis C Infection
Status: Active
Phase: Phase IV
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 12-213, NCI-2013-01103, NCT01849588
Efficacy Evaluation of TheraSphere in Patients With Inoperable Liver Cancer
Status: Active
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: TS-103, NCI-2012-01029, NCT01556490
Sorafenib Tosylate with or without Stereotactic Body Radiation Therapy in Treating Patients with Liver Cancer
Status: Active
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: RTOG-1112, NCI-2012-02057, NCT01730937
A Study of Ramucirumab (LY3009806) Versus Placebo in Participants With Hepatocellular Carcinoma and Elevated Baseline Alpha-Fetoprotein
Status: Active
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 15755, NCI-2016-00158, 2014-005068-13, I4T-MC-JVDE, NCT02435433
A Study of Nivolumab Versus Sorafenib as First-Line Treatment in Patients With Advanced Hepatocellular Carcinoma
Status: Active
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: CA209-459, NCI-2015-01952, NCT02576509
Hepatocellular Carcinoma Study Comparing Vaccinia Virus Based Immunotherapy Plus Sorafenib vs Sorafenib Alone
Status: Active
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: JX594-HEP024, NCI-2016-00198, NCT02562755
A Study of BBI608 Administered With Paclitaxel in Adult Patients With Advanced Malignancies
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: BBI608-201, NCI-2014-01566, NCT01325441
Phase I/II Study of IMMU-132 in Patients With Epithelial Cancers
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: IM-T-IMMU-132-01, NCI-2014-00136, NCT01631552
A Study to Evaluate the Effectiveness, Safety and Tolerability of Nivolumab and the Combination Nivolumab Plus Ipilimumab in Patients With Advanced Liver Cancer
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: CA209-040, NCI-2013-00864, 2012-001514-42, NCT01658878
Tivozanib in Treating Patients with Liver Cancer That Is Metastatic or Cannot Be Removed by Surgery
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: I 229112, NCI-2013-00756, NCT01835223
Hydroxychloroquine Sulfate with TACE in Treating Patients with Liver Cancer That Cannot Be Removed by Surgery
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: UPCC 22213, NCI-2014-00398, 818625, NCT02013778
A Study of LY2875358 in Combination With Ramucirumab (LY3009806) in Participants With Advanced Cancer
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 15246, NCI-2014-02649, I4C-MC-JTBF, NCT02082210
Ipilimumab and Hypofractionated Stereotactic Body Radiation Therapy in Treating Patients with Advanced Solid Malignancies
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 2013-0882, NCI-2015-00042, NCT02239900
A Study of BBI608 in Combination With Sorafenib, or BBI503 in Combination With Sorafenib in Adult Patients With Hepatocellular Carcinoma
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: BBIHCC-103, NCI-2014-02447, BBI608-503-103HCC, NCT02279719
Trial of TRC105 and Sorafenib in Patients With HCC
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: 105HCC101, NCI-2016-00131, NCT02560779
Enzalutamide with or without Sorafenib Tosylate in Treating Patients with Advanced Liver Cancer
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 15-279, NCI-2016-00062, NCT02642913
Temsirolimus and Sorafenib Tosylate in Treating Patients With Stage II-IV Liver Cancer
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 to 85
Trial IDs: 124511, NCI-2012-02021, NCT01687673
Sorafenib Tosylate and Combination Chemotherapy in Treating Patients with Advanced Liver Cancer
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 12-218, NCI-2013-00627, NCT01775501
Sorafenib Tosylate and Doxorubicin Hydrochloride in Treating Patients with Advanced Liver Cancer
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 12-259, NCI-2013-00867, NCT01840592
Sorafenib Tosylate and Yttrium Y 90 Glass Microspheres in Treating Patients with Liver Cancer That Cannot Be Removed by Surgery
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 2012-0870, NCI-2013-01667, Y-90, NCT01900002
Phase 2, Randomized, Double-Blind, Placebo-Controlled of the Efficacy and Safety of CF102 in Hepatocellular Carcinoma (HCC)
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: CF102-201HCC, NCI-2016-00211, NCT02128958
Ponatinib Hydrochloride in Treating Patients with Advanced Biliary Cancer with FGFR2 Fusions
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: MC1345, NCI-2014-02075, NCT02265341
Sequential Melphalan for Use With Hepatic Delivery System Treatment Followed by Sorafenib in Patients With Unresectable HCC
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: PHP-HCC-201, NCI-2015-00604, NCT02406508
A Study of MEDI4736 With Tremelimumab, MEDI4736 or Tremelimumab Monotherapy in Unresectable Hepatocellular Carcinoma
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: D4190C00022, NCI-2016-00207, NCT02519348
Oncolytic HSV-1 rRp450 in Treating Patients with Primary Liver Cancer
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 09-042, NCI-2010-01930, NCT01071941
Start Over